Febuxostat for Gout: How It Works, Who It's For, and the Heart Question

Your body makes uric acid with an enzyme called xanthine oxidase. Think of it as a tap that keeps topping up the urate in your blood. Febuxostat reaches back and turns that tap down. Technically it is a selective, non-purine inhibitor of xanthine oxidase¹, which is a precise way of saying it clamps onto that one enzyme and slows how much uric acid you make in the first place.

That is the same job allopurinol does, by a slightly different route. Lower the production, and there is less urate to crystallize, less to settle into a joint at 3 a.m. The number both drugs are aiming for is a blood urate level below 6 mg/dL, the point at which existing crystals stop growing and slowly dissolve². In the UK, NICE writes the same target as below 360 micromol/litre⁴, which is the same line drawn in different units.

Here is the strange part. You will not feel febuxostat working. There is no rush of relief, no signal that the medicine is doing its job. The good news arrives as an absence, as flares that simply stop turning up. That takes patience, and it is worth it.

For most people starting urate-lowering therapy in the US, allopurinol is the first choice. The ACR names it as the preferred first-line option, including for people with moderate-to-severe chronic kidney disease³. So febuxostat is usually the second door you try, not the first, and that is by design rather than a knock against it.

The second door matters when the first one closes. If allopurinol gives you a rash or a hypersensitivity reaction, or it simply cannot get your urate down to target even at a proper dose, febuxostat becomes a real alternative that works through the same tap, by another mechanism. For people who cannot tolerate allopurinol, having a second xanthine oxidase inhibitor to switch to is exactly why it exists.

The UK guidance draws the line a little differently, and it is worth knowing. NICE offers either allopurinol or febuxostat as a first-line choice when you start treat-to-target therapy⁴, rather than ranking one above the other. Two respected bodies, one small honest disagreement. What matters is that both treat febuxostat as a legitimate way to lower uric acid, not a last resort.

Febuxostat is typically started at a low dose, under 40 mg a day, and then increased over time until your urate reaches target⁵. Starting low is not caution for its own sake. Dropping uric acid quickly can shake loose the crystals that are already sitting in your joints, and a loosened crystal can set off a flare on its way out.

That leads to the cruel irony of every urate-lowering drug: the flares can pick up before they settle down. This is a sign the medicine is working, not failing. Because of it, guidelines recommend taking an anti-inflammatory alongside your febuxostat for the first three to six months, not less⁶. NICE names low-dose colchicine as the usual cover, with a low-dose NSAID or steroid if colchicine does not suit you⁴.

Once you are on it, the job is to keep going and to keep checking. Your clinician will usually retest your urate over the following months and nudge the dose until you are reliably under target, then keep you there. Febuxostat only works while you take it, so this is a long commitment rather than a short course. Stopping quietly lets the urate climb back up.

You have probably read something frightening about febuxostat and the heart. Here is what the evidence actually says, without the scare quotes. A large safety trial called CARES compared febuxostat with allopurinol in people who mostly already had cardiovascular disease. Febuxostat did as well as allopurinol on the main measure of heart problems, but it carried a higher rate of death: the hazard ratio for death from any cause was 1.22, and for death from cardiovascular causes it was 1.34⁷.

That is a real signal, and it deserves respect rather than panic. It does not mean febuxostat causes heart attacks, and it does not mean the drug is dangerous for everyone. What it means is that if you already have a history of heart disease, the balance shifts. In response to this evidence, the ACR conditionally recommends that people taking febuxostat who have a history of cardiovascular disease, or who have a new cardiac event, consider switching to an alternative urate-lowering drug if one is available⁸.

For someone with a healthy heart, this is a footnote worth knowing. For someone with a cardiac history, it is a genuine conversation to have with your clinician before you start, or if your circumstances change while you are on it. Neither of those is a reason for shame. It is just the kind of trade-off that good medicine weighs out loud instead of hiding.

Beyond the heart question, febuxostat is generally well tolerated. The most commonly reported issues are changes in liver blood tests, some nausea or stomach upset, and occasional joint pain, which is why liver function is usually checked from time to time while you are on it. Serious skin reactions are uncommon, though no urate-lowering drug is entirely free of them.

Febuxostat also should not be combined with certain other medicines, azathioprine being the important one, because slowing xanthine oxidase changes how that drug clears from your body. This is exactly the kind of interaction your clinician and pharmacist screen for, so the practical move is simple: make sure whoever prescribes it has your full medication list. If anything new turns up, such as a spreading rash, yellowing skin, or chest symptoms, that is a call-your-clinician moment rather than a wait-and-see one.